Risk of irAEs in Patients With Autoimmune Diseases Treated With ICIs for Stage III or IV Melanoma
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
Risk of irAEs in patients with autoimmune diseases treated by immune checkpoint inhibitors for stage III or IV melanoma: results from a matched case-control study
Ann. Rheum. Dis 2022 Jul 04;[EPub Ahead of Print], L Plaçais, S Dalle, O Dereure, S Trabelsi, S Dalac, D Legoupil, H Montaudié, JP Arnault, J De Quatrebarbes, P Saiag, F Brunet-Possenti, T Lesimple, E Maubec, F Aubin, F Granel-Brocard, JJ Grob, PE Stoebner, C Allayous, B Oriano, C Dutriaux, L Mortier, C LebbeFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.